Myoclonic dystonia

AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia

Retrieved on: 
Monday, April 5, 2021
Organ systems, Branches of biology, Drugs, Neurological disorders, Dystonia, Spasmodic torticollis, Botulinum toxin, Torsion dystonia, Myoclonic dystonia

The first patient dosed in our cervical dystonia study represents an important milestone as we advance our development programs for the therapeutic uses of ABP-450, said Marc Forth, Chief Executive Officer of AEON Biopharma.

Key Points: 
  • The first patient dosed in our cervical dystonia study represents an important milestone as we advance our development programs for the therapeutic uses of ABP-450, said Marc Forth, Chief Executive Officer of AEON Biopharma.
  • Botulinum toxin is the standard of care for the treatment of cervical dystonia, helping to improve pain, posture, and disability.
  • The Phase 2 trial will evaluate the efficacy and safety of ABP-450 in adults with a clinical diagnosis of cervical dystonia.
  • AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions.

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Retrieved on: 
Saturday, May 23, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Organ systems, Drugs, Nervous system, Botulism, Neurological disorders, Dystonia, Botulinum toxin, Spasmodic torticollis, Spasticity, Bont, Neurotoxin, Myoclonic dystonia, the Carenity 2 surveys, spasticity, cervical dystonia, Ipsen

The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.

Key Points: 
  • The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.
  • Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives.
  • Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year.
  • How do patients with cervical dystonia (CD) experience their botulinum neurotoxin type a (BoNT-A) treatment cycle: results from an international online survey.

Global Cervical Dystonia Therapeutics Market to 2023: Alternatives to Botulinum Toxins and Other Therapeutics will Provide Market Challenges

Retrieved on: 
Wednesday, November 21, 2018
Neurology, Medicine, Botulinum toxin, Botulism, Neurotoxins, Plastic surgery, Toxins, Toxicology, Dystonia, Spasmodic torticollis, Myoclonic dystonia

The cervical dystonia therapeutics market will register a CAGR of almost 5% by 2023.

Key Points: 
  • The cervical dystonia therapeutics market will register a CAGR of almost 5% by 2023.
  • With the rise in reimbursement programs for botulinum neurotoxin injections, there is a growing demand for treatment of cervical dystonia.
  • Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia.
  • The global cervical dystonia therapeutics industry is forecasted to witness a steady growth owing to the expected approval of late-stage molecules in the pipeline for the treatment of cervical dystonia.